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Abstract 
Treatment in patients with atrial fibrillation or venous thromboembolism in recent decades has been based almost 
exclusively on the use of vitamin K antagonists. These drugs have a narrow therapeutic index, so it is precise to 
repeated adjustments of doses that require analytical monitoring. For many years it has advocated the need to have 
more convenient new antithrombotic drugs. So is developing a new generation of antithrombotic not related to 
coumarin. In 2008 and 2009, two of these new anticoagulants have been registered and approved in Europe and Ca-
nada-these are dabigatran etexilate (Pradaxa ®) and rivaroxaban (Xarelto ®). Anticoagulant dabigatran is the first 
direct thrombin inhibitor, orally available. Specifically and reversibly inhibits thrombin, so the duration of action 
is predictable. The anticoagulant effect correlates well with plasma drug concentrations, which implies an effective 
anticoagulation with low bleeding risk without major problems of interactions with other drugs. Rivaroxaban is first 
oral anticoagulant inhibitor of factor Xa (FXa). It produces a predictable and reversible inhibition of FXa activity 
with ability to inhibit clot-bound FXa. The predictable pharmacokinetics and pharmacodynamics characteristics 
of dabigatran and rivaroxaban may facilitate dental management of patients who until now have been in treatment 
with traditional anticoagulants, given that it doesn’t require routine laboratory monitoring in the vast majority of 
patients treated. They also present a profile of drug interactions very favourable.
Key words: Dabigatran, rivaroxaban, warfarin, heparin, anticoagulants, dentistry.
Gómez-Moreno G, Aguilar-Salvatierra A, Martín-Piedra MA, Guardia J, 
Calvo-Guirado JL, Cabrera M, López-Gallardo C, Castillo T. Dabigatran 
and rivaroxaban, new oral anticoagulants. new approaches in dentistry. J 
Clin Exp Dent. 2010;2(1):e1-5.     
 http://www.medicinaoral.com/odo/volumenes/v2i1/jcedv2i1p1.pdf
Article Number: 678928           http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
e2
J Clin Exp Dent. 2010;2(1):e1-5.                                       Dabigatran and rivaroxaban in dentistry.
Introduction
Oral anticoagulants are a group of drugs used to treat 
many cardiovascular diseases, such as in the prophylaxis 
of systemic embolism (whose risk is increased in patients 
with atrial fibrillation or have undergone orthopaedic 
surgery) (1). The vitamin K antagonists, among which 
are warfarin and acenocoumarol, have low therapeutic 
index (2) as its pharmacological management is diffi-
cult and need continuous monitoring, also have multiple 
interactions with other drugs and food (3). Many of the 
patients being treated with warfarin have an inadequa-
te anticoagulation. Despite the great effort in creating 
protocols of care and appropriate use of anticoagulants 
available, the results in clinical practice are by no means 
desired (4). From this, comes the need for new anticoa-
gulant agents that are effective, safe and easy to use. 
After a time when there have been little pharmacologi-
cal innovations in the field of anticoagulants, the recent 
emergence of new oral anticoagulants has generated high 
expectations. Special attention should be given to direct 
thrombin inhibitors (dabigatran) and FXa inhibitors (ri-
varoxaban). These new drugs have similar effectiveness 
to traditional drugs, though, have fewer side effects. In 
addition, dental management of patients treated with the 
new anticoagulants may be easier because it does not 
require monitoring.
Dabigatran
Dabigatran etexilate (Pradaxa ®, Boehringer Ingelhe-
im, Spain) is the first anticoagulant and reversible direct 
inhibitor of thrombin available orally. Specifically and 
reversibly inhibits thrombin, which is the key enzyme 
of the cascade of the coagulanlation (Fig. 1). It has a 
bioavailability values of 5% and once absorbed is con-
verted in the liver to its active metabolite, dabigatran, 
which is mostly eliminated by the kidneys (80%) (Table 
1). The absorption of the Prodrug dabigatran extexilate 
and it’s conversion to dabigratan is faster. The maximum 
plasma concentration was reached between 30 minutes 
and 2 hours after oral administration, leading to a rapid 
onset of effect with a half life of 12 to 17 hours (5). Des-
pite the low oral bioavailability, it shows low variability 
among individuals. Studies in both healthy volunteers 
and patients undergoing major orthopaedic surgery have 
indicated that it allows fixed dosing regimens. The anti-
coagulant effect correlates well with plasma drug con-
centrations, which implies an effective anticoagulation 
with low bleeding risk. 
Dabigatran versus heparin
The dabigatran has been evaluated as prophylactic 
thromboembolism venous dose of 150 mg or 220 mg 
orally after hip replacement surgery and knee, compa-
red with enoxaparin 40 mg orally (low molecular weight 
heparin) (6-8). The results of these studies were similar 
Fig.1. Mechanism of action of dabigatran, rivaroxaban and warfarin.
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for both drugs in both surgical procedures. Furthermore, 
dabigatran bleeding has been associated with clinically 
less relevant than those produced by current patterns of 
low molecular weight heparins (9).
Dabigatran versus warfarin
The clinical effectiveness of dabigatran, which acts at 
the end of the coagulation cascade (10), seems to be very 
different from the effect of warfarin, which acts almost 
at all levels of the cascade. Recent studies that have 
compared warfarin and dabigatran show the latter as a 
substitute for warfarin in patients with atrial fibril, whe-
re the risk of thromboembolic events systemic level is 
increased (5,11,12).Connolly et al. (2009) (12) have re-
cently published the results of an evaluation of long-term 
anticoagulant therapy, comparing dabigatran, at doses of 
110 mg and 150 mg twice daily with warfarin (classical 
pharmacological therapy of atrial fibrillation). The trial 
was conducted in 18,113 patients with atrial fibrillation 
for 2 years. The study results suggest that therapy with 
dabigatran 150 mg twice daily is linked to lower rates of 
stroke and systemic embolism, although, the incidence 
of major bleeding events is similar when compared with 
the results of warfarin. There were no significant diffe-
rences in mortality between patients. Despite having si-
milar effects in terms of incidence of bleeding, treatment 
with dabigatran did not require continuous monitoring 
and was not associated with the emergence of significant 
adverse effects (11). In this sense, it has been sugges-
ted that patient adherence to dabigatran will be better 
than warfarin. The new drug is more expensive, but can 
greatly allow reduce costs due to the decrease in the rate 
of heart attacks, plus the fact of not requiring continuous 
monitoring. Therefore, some authors have advocated the 
dabigatran as a substitute in the near future of warfarin 
as therapy of choice for prevention of thromboembolic 
events and stroke in patients with atrial fibrillation, but 
still need more studies that reveal the possible adverse 
drug reactions long-term (11).
Rivaroxaban
Rivaroxaban (Xarelto ®, Bayer HealthCare and Johnson 
& Johnson Pharmaceutical Research & Development) is 
the first oral anticoagulant drug direct inhibitor of acti-
vated factor X (FXa) of clotting. It is a derivative of oxa-
zolidone able to inhibit free factor Xa and / or attached 
to the prothrombinase complex. This inhibition disrupts 
the intrinsic and extrinsic pathways of coagulation cas-
cade, inhibiting therefore the formation of thrombin 
and thrombus formation (Fig. 1). Rivaroxaban has not 
proved effective over the platelet action. Recent clinical 
trials have shown that anticoagulation can be predicted 
in patients with no need to adjust or monitor them. Has 
more than 80% bioavailability after oral administration, 
is metabolized by the liver and 66% is excreted in the 
urine (Table 1) The purpose of this new oral anticoagu-
lant is to replace vitamin K antagonists in the prevention 
of venous thromboembolism and arterial embolism in 
patients with atrial fibrillation. This FXa inhibitor has 
been evaluated in several phase III trial studies, to study 
it’s use in secondary thombroprophylaxis in major or-
thopaedic surgery, used in doses of 10 mg orally (13-15). 
Rivaroxaban has been shown to be significantly more 
effective than treatment with enoxaparin.
New approaches in dentistry
The dental management of patients on oral anticoagulant 
treatment should always be painstaking, and especially 
to those more invasive treatments that generate or can 
generate bleeding (tooth extraction, oral surgery ...). The 
expert in oral cavity must know the therapeutic range of 
the patient, according to the cardiovascular disease that 
he presents, and based on that, assess the potential risk 
of bleeding prior to dental treatment. The use of oral an-
ticoagulants is always controversial because of the low 
therapeutic index (2), an excessive overdose is linked 
to the occurrence of haemorrhage, whereas if there is 
insufficient plasma concentrations it increases the risk 
of thromboembolic phenomena occurring. This situa-
Warfarina Dabigatran Rivaroxaban
Type Vitamin K-dependent factors inhibitor
Direct thrombin in-
hibitor
Direct factor Xa inhi-
bitor
Half-life 2.5 days 14-17 h. 5-13 h.
Elimination 92 % renal
80 % renal
20% biliary
33% renal (un-
changed)
33% renal (as inac-
tive metabolites)
33 % biliary
Plasmatic protein 
binding 99.5 % 25-30 % 90 %
Bioavailability 100 % 5 % > 80 %
Table 1. Comparison of dabigatran and rivaroxaban with warfarin.
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tion requires continuous monitoring of INR (Internatio-
nal Normal Ratio) in the case of patients treated with 
oral coumarin anticoagulants, among which the aceno-
coumarol or warfarin (16). One of the most important 
advantages of dabigatran and rivaroxaban, compared to 
classical anticoagulants, is the lack of the need for conti-
nuous monitoring in order to maintain levels of anticoa-
gulation (12), INR values, at all times in a certain range 
depending on the patient’s cardiovascular disease. This 
does not mean that the management of patients with da-
bigatran and rivaroxaban does not require special atten-
tion. In terms of dental treatment to be done, there will 
be a number of local haemostatic measures to reduce the 
risk of bleeding. Currently there is no reduction protocol 
of the dabigatran dosage or the rivaroxaban for dental 
use. In this sense, more scientific evidence is needed to 
specify the dental management to new anticoagulants, 
although, according to scientific evidence it seems to 
be much easier due to the stability of INR that is achie-
ved with these drugs. Among other advantages of the 
new oral anticoagulants the highlight is that it has fewer 
drug interactions. Rivaroxaban does not seem to inhibit 
or induce any P450 enzyme. The rivaroxaban shows no 
relevant drug interaction with non-steroidal antiinflam-
matory drugs (NSAIDs). Contrary to what occurs with 
oral coumarin anticoagulants, which when combined 
lead to increased bleeding (3). It has been suggested 
that rivaroxaban and enoxaparin can be admistered in 
concomitantly form or in sequential therapy (17). Riva-
roxaban prolongs the bleeding time when coadministe-
red with aspirin or clopidogrel, although the relevance 
of this interaction is weak and does not affect platelet 
aggregation. Dabigatran, moreover, is not metabolized 
by the cytochrome P450 system and therefore presents 
a profile of drug without major problems of drug inte-
ractions. With regard to potential interactions with an-
timicrobial caution should be exercised only due to its 
pharmacokinetics, with clarithromycin and rifampicin. 
Regarding NSAIDs NSAIDs is not recommended to 
prescribe long biological half-life of elimination (> 12 
h) in patients treated with dabigatran. Dabigatran and 
rivaroxaban does not require coagulation monitoring in 
the currently approved indications, however, there is no 
specific antidote (18), so that in case of overdose should 
maintain adequate diuresis, haemostasis or the transfu-
sion of fresh frozen plasma (17).
Conclusions
The emergence of new oral anticoagulants, such as da-
bigatran and rivaroxaban, has in recent years generated 
great expectations in the scientific community due to: 
the similar clinical effectiveness of warfarin and enoxa-
parin over to a more predictable pharmacokinetics and 
pharmacodynamics and the adverse effects clinically 
less relevant. These new drugs appear as substitutes of 
coumarin anticoagulants and have the potential to chan-
ge the standards of clinical practice in the prevention of 
deep vein thrombosis and pulmonary embolism. The use 
of dabigatran and rivaroxaban does not require conti-
nuous monitoring of INR. Furthermore, dabigatran and 
rivaroxaban, unlike warfarin or acenocoumarol, have no 
drug interactions with NSAIDs or with most first-choice 
antimicrobials used in the dental office, so it is a dental 
management safer and easier for the professional in the 
oral cavity.
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